Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326779 | 0.77 | ALDH1A1 (0.34) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL23679501 | 0.74 | SLC2A1 (0.33) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL8043797 | 0.74 | GDA (0.36) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL22326694 | 0.73 | JAK2 (0.34) | — | |
| SCHEMBL22381533 | 0.72 | PNP (0.42) | LMNATSHRXDHBLMSMN1; SMN2 | |
| SCHEMBL22883503 | 0.71 | SLC2A1 (0.33) | SLC2A1 | |
| SCHEMBL23867234 | 0.71 | — | — | |
| SCHEMBL20325366 | 0.70 | ADORA2A (0.36) | ADORA2ARAB9ASMN1; SMN2 | |
| SCHEMBL21637050 | 0.70 | TDP1 (0.37) | LMNASLC2A1 | |
| SCHEMBL18520821 | 0.70 | SMN1; SMN2 (0.40) | ADORA2ASMN1; SMN2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | LMNA 3096/4885TSHR 1817/4885ADORA2A 17/4885 |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | LMNA 1584/4885TSHR 2299/4885ADORA2A 70/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | LMNA 2120/4885TSHR 2079/4885ADORA2A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.